Skip to content

Regenxbio RGNX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$37.8M+24.8%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$11.2M-15.6%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$2.08M+17.9%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$5.49M-3.4%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$2.19M+17.1%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$125.39K+84.9%

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's operating lease liabilities (current)?
Regenxbio (RGNX) reported operating lease liabilities (current) of $7.87M in Q1 2026.
How has Regenxbio's operating lease liabilities (current) changed year-over-year?
Regenxbio's operating lease liabilities (current) decreased by 0.9% year-over-year, from $7.94M to $7.87M.
What is the long-term trend for Regenxbio's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Regenxbio's operating lease liabilities (current) has grown at a 27.1% compound annual growth rate (CAGR), from $2.5M to $8.29M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.